Biodexa Pharmaceuticals American Depositary Shs (BDRX) vs Curis (CRIS)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Curis is the larger company by market cap ($1.6 million vs $1.0 million), about 1.6 times the size. On valuation, Biodexa Pharmaceuticals American Depositary Shs trades at a lower trailing P/E (0.0x vs 0.5x for Curis).
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | BDRX | CRIS |
|---|---|---|
| Share price | $0.4602 | $0.6712 |
| Market cap | $1.01M | $1.63M |
| 1-day change | -12.13% | -5.38% |
| P/E ratio (TTM) | 0.01 | 0.51 |
| EPS (TTM) | $63.74 | $1.32 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $52.05 | $33.60 |
| 52-week low | $0.45 | $0.61 |
| Distance from 52-week high | -99.12% | -98.00% |
| Analyst consensus | none | none |
| Avg. price target upside | +1836.11% | +6257.27% |
| Average volume | 3.72M | 199.15K |
| Shares outstanding | 2.20M | 2.43M |
| Employees | 11 | 20 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- Curis trades at a higher earnings multiple (0.5x vs 0.0x trailing P/E).
About Biodexa Pharmaceuticals American Depositary Shs
BDRX stock →Biodexa Pharmaceuticals Plc, a clinical stage biopharmaceutical company, focuses on developing a pipeline of products for the treatment of familial adenomatous polyposis, non-muscle invasive bladder cancer, and Type 1 diabetes and rare/orphan brain cancer. Its lead product candidate, Tolimidone, is a selective activator of the lyn kinase enzyme, currently under Phase II studies for the treatment of Type 1 diabetes.
Health Care · Biotechnology: Pharmaceutical Preparations · 11 employees
About Curis
CRIS stock →Curis, Inc., a biotechnology company, engages in the discovery and development of drug candidates for the treatment of human cancers in the United States. Its clinical stage drug candidates include Emavusertib, an oral small-molecule IRAK4 kinase inhibitor, which is in a Phase 1/2 open-label, single-arm expansion trial in patients with relapsed/refractory primary central nervous system lymphoma.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 20 employees
BDRX vs CRIS FAQ
Which is bigger, Biodexa Pharmaceuticals American Depositary Shs or Curis?
Curis (CRIS) is larger, with a market capitalization of $1.63M compared with $1.01M for Biodexa Pharmaceuticals American Depositary Shs (BDRX).
Which has the lower P/E ratio, BDRX or CRIS?
BDRX has the lower trailing P/E at 0.0, versus 0.5 for CRIS. A lower P/E is not by itself a sign of a better investment; it can reflect slower expected growth or higher risk.
Are Biodexa Pharmaceuticals American Depositary Shs and Curis in the same industry?
Both are in the Health Care sector, but in different industries: Biotechnology: Pharmaceutical Preparations for Biodexa Pharmaceuticals American Depositary Shs and Biotechnology: Biological Products (No Diagnostic Substances) for Curis.